Wegovy linked to 18.9 pounds of average weight loss in six months versus another treatment
A study found that semaglutide 2.4 mg, a treatment by Novo Nordisk, led to an average weight loss of 18.9 lbs (8.6 kg) over six months in patients with MASH, compared to resmetirom. The treatment also showed greater reductions in liver enzymes and cardiometabolic measures. According to Novo, these findings provide real-world insights for managing MASH.
How this was made
The 30-second read
Why it matters
The data suggest semaglutide delivers superior weight loss and liver‑enzyme improvements, providing new evidence for its efficacy in MASH.
Market read
First public disclosure of comparative real‑world outcomes could influence investor sentiment toward Novo Nordisk and the broader obesity‑treatment sector.
What to watch
Potential side‑effect profile and upcoming confirmatory trial results could temper enthusiasm.
Background
The article reports results from two retrospective real‑world studies (PLATINUM‑Truveta and RHODIUM‑2) comparing semaglutide 2.4 mg to resmetirom or no treatment in patients with metabolic dysfunction‑associated steatohepatitis (MASH).
Ticker impact
Novo Nordisk's semaglutide 2.4 mg shows 18.9 lb average weight loss vs resmetirom in a new real‑world study.
likely upward pressure as market prices in the weight‑loss advantage.
First‑time disclosure of comparative effectiveness provides fresh catalyst; investors may re‑rate the drug's market potential.
Market effects
Strengthens outlook for GLP‑1 weight‑loss market and may lift peers in obesity therapeutics.
US and European markets with exposure to obesity drugs could see modest gains.
Adds to global narrative on semaglutide's expanding indications.
Counterpoint
Skeptics may argue real‑world data are observational and could be offset by safety concerns.
Key entities
- companyNovo Nordisk
Manufacturer of semaglutide 2.4 mg.
- drugSemaglutide 2.4 mg
GLP‑1 receptor agonist approved for MASH.
